Orders for Merck ... suggested the drug was not as effective as previously thought. A 30% reduction in the risk of hospitalisation or death in people with mild or moderate COVID-19 at high ...
An FDA advisory panel has voted in favour of Merck & Co's experimental insomnia drug, saying that it is safe and effective for elderly patients at the lower of two doses studied.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback